Nautilus Biotechnology (NAUT) Operating Leases (2020 - 2026)

Nautilus Biotechnology has disclosed Operating Leases across 7 years of filings, most recently posting $25.0 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $25.0 million, down 14.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.0 million (down 14.72% YoY), and the FY2025 annual result was $26.2 million, down 0.74% from the prior year.
• Operating Leases came in at $25.0 million for Q1 2026 at Nautilus Biotechnology, down from $26.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $37.3 million in Q1 2023 to a low of $24.0 million in Q2 2025.
• The 5-year median for Operating Leases is $28.6 million (2022), against an average of $29.2 million.
• Across the five-year window, Operating Leases jumped 2213.44% in 2022 and declined 26.51% in 2025, its largest moves.
• Nautilus Biotechnology's Operating Leases stood at $28.3 million in 2022, then gained by 9.72% to $31.1 million in 2023, then decreased by 15.15% to $26.4 million in 2024, then slipped by 0.74% to $26.2 million in 2025, then retreated by 4.45% to $25.0 million in 2026.
• The last three Operating Leases figures came in at $25.0 million (Q1 2026), $26.2 million (Q4 2025), and $27.0 million (Q3 2025), per Business Quant data.